Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130™, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Source: rafapress / Shutterstock.com Crispr Therapeutics (NASDAQ: CRSP ) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. That rolling review starts in November and covers the use of exa-cel in treating SCD and TDT.

Why Is Crispr Therapeutics (CRSP) Stock Up Today?

Crispr said Tuesday it will begin asking the FDA to approve its gene-editing blood diseases treatment in November, and CRSP stock jumped. The post Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug appeared first on Investor's Business Daily.

Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug

Vertex Pharmaceuticals

CRISPR Therapeutics Inc. CRSP, +7.21% and Vertex Pharmaceuticals Inc. VRTX, +3.04% said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%.

CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that Vertex has concluded discussions with the U.S. Food and Drug Administration (FDA), and the FDA granted exagamglogene autotemcel (exa-cel) a rolling review for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Vertex will submit its biologics licensing application (BLA) for exa-cel for rolli

Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

In collaboration with stellar partners like Vertex, Crispr is aggressively expanding its robust pipeline of gene-edited medicine for various disorders. By year end, Crispr is poised to file a marketing application in Europe for exa-cel, a drug designed to treat blood disorders.

Crispr: Elucidating And Forecasting Key Developments

Amgen

Exelixis

iShares Nasdaq Biotechnology ETF

Ionis Pharma

Merck

Twist Bioscience Corp

I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.

The 7 Best Biotech Stocks to Buy

Intellia Therapeutics

These biotech companies will either sink or swim before the end of the decade.

2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years

Shares of Intellia Therapeutics Inc. NTLA, +7.36% gained 6.5% in premarket trading on Friday after the company and Regeneron Pharmaceuticals Inc. REGN, +1.18% announced positive data from an ongoing Phase 1 clinical trial evaluating their investigational Crispr therapy as a treatment for transthyretin amyloidosis with cardiomyopathy, which can cause heart failure. The data demonstrated a reduction in serum transthyretin in 12 patients for up to six months.

Intellia's stock is up 6% on data from an early-stage trial for its Crispr therapy

Amazon

Etsy

Intuitive Surgical

Moderna

These stocks have what it takes to deliver lasting gains down the road.

If You've Got $5,000, Buying These 5 Top Stocks Right Now Would Be a Genius Move

CRISPR Therapeutics AG (NASDAQ:CRSP ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 11:40 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us, everybody.

CRISPR Therapeutics AG (CRSP) Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)

Crispr Therapeutics is continuing to show strong execution. An announcement of the information release of discussions surrounding the CTX001 filing is expected in weeks.

Crispr Therapeutics: Nearing Harvest Season

CRISPR Therapeutics AG (NASDAQ:CRSP ) Citi 17th Annual BioPharma Conference September 7, 2022 8:50 AM ET Company Participants Sam Kulkarni – Chief Executive Officer Conference Call Participants Yigal Nochomovitz – Citi Yigal Nochomovitz All right, well, welcome everyone. I'm Yigal Nochomovitz, one of the biotech analysts here at Citi.

CRISPR Therapeutics AG (CRSP) Citi 17th Annual BioPharma Conference Transcript

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock?

CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?

While CRISPR Therapeutics' (CRSP) lead candidate is still a couple of years away from commercialization, it is highly dependent on collaboration revenues to fund its ongoing pipeline.

CRISPR Therapeutics' (CRSP) Pipeline Development Fuels Growth

Markforged Holding Corp

UiPath

Regeneron Pharmaceuticals

Stratasys

Tesla

Unity Software

Cathie Wood is well-known in the investment world as the face of ARK Invest, the firm she founded in 2014. ARK itself stands for Active Research Knowledge.

7 Cathie Wood Stocks to Buy on the Dip

DraftKings

Zoom Video

Beam Therapeutics

Ginkgo Bioworks Holdings

This article is excerpted from Tom Yeung's Profit & Protection newsletter dated Aug. 16, 2022. To make sure you don't miss any of Tom's picks, subscribe to his mailing list here.

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

ARK Genomic Revolution Multi-Sector ETF

Editas Medicine

Global X Genomics & Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

A Comprehensive Guide to Genomic ETFs

Americold Realty

MacroGenics

Take-Two Interactive Software

Markets were on the rise Wednesday after a relatively positive consumer price index (CPI) report.

Barclays Picks 2 Winners and 2 Losers After Earnings

CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.

CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates

Crispr Therapeutics is perhaps the most speculative name I'm currently buying, though in small sizes, with an expectation to "don't look, don't sell" for at least 10 years. Analysts expect this company to lose money for the next three years, but with a chance of earning 25-50% of its current stock price every year from 2029-2031.

Crispr: My Long-Term 'Wait And Watch' Punt On The Future Of Gene Editing

-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); discussions with the U.S. Food and Drug Administration (FDA) ongoing-

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Alnylam Pharmaceuticals

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the entire industry.

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

The next 12 months could look very different from the past year for this biotech company.

Where Will CRISPR Therapeutics Be in 1 Year?

This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

News for CRISPR Therapeutics Stock (CRSP)